Marianna Rowlands
Senior Director & Head of Respiratory Translational Science & Immunology Johnson & Johnson
Marianna Rowlands is a senior respiratory translational science and precision medicine leader with over 15 years of experience advancing biomarker strategies across discovery, translational research, and clinical development. As Senior Director and Head of Respiratory Translational Science (TS) at Johnson & Johnson Immunology, Marianna leads the Respiratory TS strategy, integrating biomarkers, multi-omics, imaging and clinical endpoints to guide patient selection and monitor therapeutic response in Respiratory indications across the portfolio. Previously in her career, Marianna advanced programs from discovery to late stage development and led biomarker and patient stratification strategies across respiratory and other immunology indications.
Seminars
This interactive workshop will focus on the critical role of biomarkers in shaping the future of COPD treatment. Participants will learn how emerging biomarkers can inform patient selection, monitor therapeutic response, and de-risk early-phase programs. The session will highlight strategies for multi-omics integration, linking biomarkers with imaging and clinical data, and translating molecular insights into actionable approaches for more precise COPD management.
Workshop Highlights
- Understand current biomarker gaps and why validated predictive and pharmacodynamic markers are urgently needed beyond blood eosinophils to guide therapy development
- Explore multi-omics strategies to identify disease-driving pathways and molecular endotypes, enabling more precise patient stratification and tailored interventions
- Learn how biomarkers can inform early decisions, optimizing patient selection, trial design, and monitoring of treatment response
- Evaluate integrated approaches that combine biomarker, imaging, and clinical data to strengthen translational insights and improve therapeutic targeting
- Gain insight into clinical and regulatory considerations, including challenges in developing biomarkers that are both actionable and meaningful for guiding treatment strategies
